Navigation Links
Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
Date:12/5/2007

in which we have successfully achieved several major goals," said Edward Lanphier, president and CEO of Sangamo. "The progress that we have made this year in both clinical and business development activities put us in a very strong position to continue to advance and commercialize our ZFP technology in therapeutics, plant agriculture, laboratory reagents and enhanced cell-lines for pharmaceutical protein manufacturing. We expect 2008 to be another year of significant accomplishments for Sangamo as we achieve a number of major value-creating events."

Mr. Lanphier continued, "We presented positive top-line clinical data from our Phase 1b trial of our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) for the treatment of diabetic neuropathy (DN). Sangamo is building on this positive data by initiating further clinical trials as we continue our efforts to develop this technology as a novel platform for therapeutic development. This year we also achieved our goal of successfully completing the accrual of subjects to the Phase 2 trial of SB-509 for DN which will give us data in the second half of 2008. In addition to our two Phase 2 clinical trials in DN, we have announced our plans to initiate further Phase 2 studies of SB-509 in stem cell mobilization and amyotrophic lateral sclerosis (ALS) and to initiate two Phase 1 clinical trials in ZFP-mediated gene modification for glioblastoma and HIV/AIDS. We have also advanced and expanded our preclinical pipeline and presented data from several programs at major scientific and medical meetings.

"We also continued to monetize our technology outside of the human therapeutic space. This year we established a major relationship with Sigma-Aldrich Corporation to develop and commercialize ZFP-based laboratory research reagents. We also entered into several cell-line engineering collaborations including a commercial license agreement with Genenetech. The research phase of our co
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... July 28, 2014 The Oakwood Foundation ... Birkhill, Wang, Songe and Associates, PC that will benefit ... tomorrows to come. , The HBWS group is ... more than $2.5 million in donations. Through their latest ... for the Oakwood Women’s Healthcare Classic for the next ...
(Date:7/28/2014)... regions in the brain was able to arouse animals ... In the August issue of Anesthesiology , investigators ... with continuous doses of either agent would move, raise ... electrical stimulation delivered to the ventral tegmental area (VTA). ... substantia nigra, did not induce the animals to wake ...
(Date:7/28/2014)... The report, “Blowing Agents Market by Type, ... Forecasts to 2019” defines and segments the global ... the global consumption volume and value. , Browse ... figures spread through 226 Pages and in-depth TOC ... Blowing agents are highly utilized materials as a ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
... plans are partnering with physician practices to initiate a range ... these programs have resulted in decreased emergency room (ER) use, ... by the Alliance of Community Health Plans (ACHP), are part ... way community health plans partner with providers to improve care. ...
... Risk Factors for,Developing MS, UB Study Shows, ... insufficiency (CCSVI), which has attracted global attention as possibly being ... for the presence of risk factors in subjects who do ... study of 252 volunteers has found an association between CCSVI ...
... HealthDay Reporter , WEDNESDAY, Nov. 30 (HealthDay News) ... drink or doing some last-minute grooming, a large majority of ... distracted while behind the wheel, a new poll shows. ... adults who drive on a regular basis admitted to having ...
... health care workers at risk of 2009 H1N1 infection during ... according to a study published in the December issue of ... the Society of Healthcare Epidemiology of America. ... Prevention (CDC), tracked 63 Southern California health care workers who ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women ... those with other forms of breast cancer to have a ... finds. Swedish researchers examined the family history, pathology reports ... 1980 and 2008. About 40 percent of the women had ...
... About 40 percent of young adults who,ve attempted suicide made ... thoughts and behavior may begin much younger than previously believed, ... ongoing survey, University of Washington researchers asked almost 900 young ... attempts. Nearly 9 percent (78) of the participants said ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
(Date:7/28/2014)... 2014  A prospective study conducted by the ... has validated the performance of VolparaDensity breast imaging ... volumetrically assessed breast density measurements to breast cancer ... Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated measurement ... breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... ORLANDO, Fla. , July 28, 2014 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development, ... that it has filed definitive proxy materials with ... its 2014 Annual Meeting of Shareholders to be ... a.m., East Standard Time. The record date for ...
(Date:7/28/2014)... 28, 2014  ResMed (NYSE: RMD ), ... treatment of sleep-disordered breathing and other chronic respiratory conditions, ... against Taiwanese medical device manufacturer APEX Medical ... APEX WiZARD 210 and 220 masks.  The judgment was ... Munich , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... is the largest barrier to routine HIV testing by ... by Janssen Therapeutics, Division of Janssen Products, LP, in ... belief by most physicians surveyed (93 percent) that HIV ... African-American community, findings suggested that only one-third of all ...
... 1, 2011 Reportlinker.com announces that a ... its catalogue: Sustained Release ... http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens ... injectable drugs to increase the duration of ...
Cached Medicine Technology:Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 2Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 3Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 4Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 2Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 3
Inquire...
... non-contact diagnostic lens, doctors have to make a ... high magnification. Now, with the Digital Wide ... can have both in one lens. This ... in a non-contact lens paired with the higher ...
... portability & capability together in this user-friendly, ... desktop maginifcation., ,With its battery powered option, ... meet any individual, education or business environment ... a briefcase from room to room or ...
... can have accurate patient information and secure dictation ... track of patient schedules, manage daily workflow and ... PC handheld device. PhysAssist IQ is a handheld ... does not require physicians to change the way ...
Medicine Products: